FDA批准
FDA批准礼来Imlunestrant用于ESR1突变的ER+/HER2-晚期乳腺癌，中国亦已申报上市
FDA批准礼来Imlunestrant（Inluriyo）治疗ESR1突变乳腺癌，中国NDA同步受理，或成为继Elacestrant后又一口服SERD新选择。
FDA批准
FDA批准礼来Imlunestrant（Inluriyo）治疗ESR1突变乳腺癌，中国NDA同步受理，或成为继Elacestrant后又一口服SERD新选择。
FDA approval
The FDA has approved imlunestrant (Inluriyo) for ESR1-mutated ER+, HER2- metastatic breast cancer. With elacestrant already on the market, patients now have two oral SERDs — raising questions of sequencing, safety, and access.